

25<sup>th</sup> November, 2023

- |   |   |
|---|---|
| <p>(1) BSE Ltd<br/>Listing Department<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai 400 001<br/><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Ltd<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051<br/><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II,<br/>L-1840 Luxembourg</p>                        |   |

Dear Sir / Madam,

**Sub: Update on acquisition of additional stake in Cipla Maroc SA**

In compliance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 4<sup>th</sup> August, 2022, we hereby notify that pursuant to the Share Purchase Agreement dated 26<sup>th</sup> September, 2022 and first amendment to Share Purchase Agreement dated 13<sup>th</sup> November, 2023, executed between the Cipla (EU) Limited, wholly owned subsidiary of the Company in UK, (“Cipla EU”), Cipla Maroc SA, Morocco, (“JV Co.”), The Pharmaceutical Institute (“PHI”) and Societe Marocaine De Cooperation Pharmaceutique (“Cooper Pharma”), Cipla EU has completed acquisition of additional 15.10% in the JV Co. from PHI for a consideration of MAD 81.1 million on 24<sup>th</sup> November, 2023.

Accordingly, Cipla EU will now hold 75.10% stake in the JV Co. and balance 24.90% stake will be held by Cooper Pharma.

Please take the above information on record.

Yours faithfully,  
**For Cipla Limited**

**Rajendra Chopra**  
**Company Secretary**

Prepared by: Mandar Kurghode